clinical trial · NCT06848231
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
Dasher Neuroscience Inc.·phase2·recruiting·n = 75
Multiple System AtrophyYA-101Placebo
brief summary
This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
started
Mar 3, 2025
primary completion
Jun 30, 2026
completion
Dec 31, 2026
last updated
Apr 29, 2026
detailed description
The purpose of the study is to evaluate 2 doses of YA-101 compared to placebo in MSA patients, including: 1) safety and tolerability, 2) pharmacokinetics, and 3) potential efficacy of YA-101.
official title
A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol